The U.S. Food and Drug Administration's Gastroenterology and Urology Devices Panel has recommended approval of Solesta as a treatment for fecal incontinence, a condition afflicting many Americans, primarily women, according to an Oceana Therapeutics news release.
Solesta is an injectable gel that has been developed to be administered in an outpatient setting without the need for anesthesia. The purpose of the product is to expand the submucosal layer of a patient's anal canal to improve bowel control.
Read the news release about Solesta as an approved fecal incontinence product.
Read other coverage about gastroenterology:
- Allergan Seeks Approval for Lap-Band Surgery for Less Obese Patients
- 3 Ways to Increase Savings for Surgery Center Supplies
- Best Practice: Applying Abdominal Pressure for More Successful Colonoscopy Screenings
Solesta is an injectable gel that has been developed to be administered in an outpatient setting without the need for anesthesia. The purpose of the product is to expand the submucosal layer of a patient's anal canal to improve bowel control.
Read the news release about Solesta as an approved fecal incontinence product.
Read other coverage about gastroenterology:
- Allergan Seeks Approval for Lap-Band Surgery for Less Obese Patients
- 3 Ways to Increase Savings for Surgery Center Supplies
- Best Practice: Applying Abdominal Pressure for More Successful Colonoscopy Screenings